Top

Published in:

01-06-2006 | Review Article

Antimicrobials, mucosal coating agents, anesthetics, analgesics, and nutritional supplements for alimentary tract mucositis

Authors: Andrei Barasch, Sharon Elad, Arnold Altman, Kathryn Damato, Joel Epstein

Published in: Supportive Care in Cancer | Issue 6/2006

Abstract

This review focuses on the value of several groups of agents for the prevention and treatment of mucositis. The review refers to alimentary mucositis as a generalized term that includes oral mucositis and gastrointestinal mucositis. This paper is part of the systematic review made by the mucositis study group which operates in the Multinational Association of Supportive Care in Cancer (MASCC)/International Society of Oral Oncology (ISOO). Several new guidelines are suggested in this review as an update to the primary systematic review that was published by the same group in 2004.

Rubenstein EB, Peterson DE, Schubert MM, Keefe D, McGuire D, Epstein JB et al (2004) Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer 100(Suppl 9):2026–2046PubMedCrossRef

Barasch A, Peterson DE (2003) Risk factors for ulcerative oral mucositis in cancer patients: unanswered questions. Oral Oncol 39:91–100PubMedCrossRef

Sonis ST, Elting LS, Keefe D, Peterson DE, Schubert MM, Hauer-Jensen M et al (2004) Perspectives on cancer therapy-induced mucosal injury. Cancer 100(Suppl 9):1995–2025PubMedCrossRef

Logan R (2002) Oral mucositis-current concepts and management. Roy Aust Coll Dent Surg 16:54–57

Slatkin NE (2003) Topical ketamine in the treatment of mucositis pain. Pain Med 4:298–303PubMedCrossRef

Luglie PF (2002) Prevention of periodontopathy and oral mucositis during antineoplastic chemotherapy. Minerva Stomatol 51:231–239PubMed

Vokurka S, Bystricka E, Koza V, Scudlova J, Pavlicova V, Valentova D et al (2005) The comparative effects of povidone-iodine and normal saline mouthwashes on oral mucositis in patients after high-dose chemotherapy and APBSCT-results of a randomized multicentre study. Support Care Cancer 13:554–558PubMedCrossRef

Adamietz IA, Rahn R, Bottcher HD et al (1998) Prophylaxis with povidone-iodine against induction of oral mucositis by radiochemistry. Support Care Cancer 6:373–377PubMedCrossRef

Stockman MA (2003) Oral mucositis and selective elimination of oral flora in head and neck cancer patients receiving radiotherapy: a double-blind randomized clinical trial. Br J Cancer 88:1012–1016CrossRef

10.

El-Sayed S (2002) Prophylaxis of radiation-associated mucositis in conventionally treated patients with head and neck cancer: a double-blind, phase III randomized controlled trial evaluating the clinical efficacy of an antimicrobial lozenge using a validated mucositis scoring system. J Clin Oncol 20:3956–3963PubMedCrossRef

11.

Cheng KKF (2004) Prevention of oral mucositis in pediatric patients treated with chemotherapy: a randomized, cross-over trial comparing two protocols of oral care. Eur J Cancer 40:1208–1216PubMedCrossRef

12.

Melo de Brito Costa E (2003) Evaluation of an oral preventive protocol in children with acute lymphoblastic leukemia. Pesqui Odontol Bras 17:147–150CrossRef

13.

Dodd MJ (2003) Radiation-induced mucositis: a randomized clinical trial of micronized sucralfate vs. salt and soda mouthwashes. Cancer Investig 21:21–33CrossRef

14.

Nottage M (2003) Sucralfate mouthwash for prevention and treatment of 5-florouracil-induced mucositis: a randomized placebo-controlled study. Support Care Cancer 11:41–47PubMed

15.

Demarosi F (2004) Transdermal fentanyl in hematopoietic stem cell transplant patients: an open trial using transdermal fentanyl for the treatment of oral mucositis pain. Bone Marrow Transplant 33:1247–1251PubMedCrossRef

16.

Drake R (2004) Opioid rotation in children with cancer. J Palliat Med 7:419–422PubMedCrossRef

17.

Cerchietti LCA (2002) Effect of topical morphine for mucositis-associated pain following concomitant chemoradiotherapy for head and neck carcinoma. Cancer 95:2230–2236PubMedCrossRef

18.

Shaiova I (2004) Tolerability and effects of two formulations of oral transmucosal fentanyl citrate in patients with radiation-induced oral mucositis. Support Care Cancer 12:268–273PubMedCrossRef

19.

Peterson DE, Petit R (2003) Phase III study: AES-14 in chemotherapy patients at risk for mucositis (abstract 2917). Prog Proc Am Soc Clin Oncol 22:725

20.

Pytlik R (2002) Standardized parenteral alanyl-glutamine dipeptide supplementation is not beneficial in autologous transplant patients: a randomized, double-blind placebo-controlled study. Bone Marrow Transplant 20:953–961CrossRef

21.

Thornley I (2004) A multiagent strategy to decrease regimen-related toxicity in children undergoing allogenic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 10:635–644PubMedCrossRef

22.

Bolwell B (2004) A prospective randomized trial comparing cyclosporine and short course methotrexate with cyclosporine and mycophenolate moeftil for GVHD prophylaxis in myeloablative allogenic bone marrow transplantation. Bone Marrow Transplant 34:621–625PubMedCrossRef

23.

Cutler C (2004) Sirolimus and tacrolimus without methotrexate as GVHD prophylaxis after matched related donor peripheral blood stem cell transplantation. Biol Blood Marrow Transplant 10:328–336PubMedCrossRef

24.

van’t Land B (2004) Role of curcumin and the inhibition of NF-kB in the onset of chemotherapy-induced mucosal barrier injury. Leukemia 18:276–284CrossRef

25.

Rezvani M (2004) Modification of radiation-induced acute oral mucositis in the rat. Int J Radiat Biol 80:177–182PubMedCrossRef

Title: Antimicrobials, mucosal coating agents, anesthetics, analgesics, and nutritional supplements for alimentary tract mucositis
Authors: Andrei Barasch
Sharon Elad
Arnold Altman
Kathryn Damato
Joel Epstein
Publication date: 01-06-2006
Publisher: Springer-Verlag
Published in: Supportive Care in Cancer / Issue 6/2006
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-006-0066-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2006

Growth factors and cytokines in the prevention and treatment of oral and gastrointestinal mucositis

Promulgation of guidelines for mucositis management: educating health care professionals and patients

Alimentary tract mucositis in cancer patients: impact of terminology and assessment on research and clinical practice

Anti-inflammatory agents in the management of alimentary mucositis

Developing evidence-based guidelines for management of alimentary mucositis: process and pitfalls

Abstracts

Keynote webinar | Spotlight on antibody–drug conjugates in cancer